Cancer Res 1998, 58:3761–3764 PubMed 35 Laga AC, Zander DS, Cagl

Cancer Res 1998, 58:3761–3764.PubMed 35. Laga AC, Zander DS, Cagle PT: Prognostic significance of cyclooxygenase 2 expression in 259 cases on non-small cell lung cancer. Arch Pathol Lab Med 2005, 129:1113–1117.PubMed 36. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, Ochiai A: Increased cyclooxygenase 2 (COX-2)

expression occurs frequently in precursor lesions of human adenocarcinoma Selleck Evofosfamide of the lung. Lung Cancer 2000, 30:73–81.PubMedCrossRef 37. Yamaguchi NH, Lichtenfels AJ, Demarchi LM, da Silva AP, Garippo AL, Alves VF, Michelin C, Azevedo PM, Moya T, Takagaki T, Saldiva PH, Vollmer RT, Capelozzi VL: COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil. Am J Clin Pathol 2004, 121:78–86.PubMedCrossRef 38. Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, Vujaskovic Z, Kelley MJ: Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol 2009, in press. 39. Staurosporine price Richardson

CM, Richardson D, Swinson DE, Swain WA, Cox G, O’Byrne KJ: Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 2005,48(1):47–57.PubMedCrossRef 40. Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett SM: EGFR signaling is required for TGF-b1-mediated COX-2

induction in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2007, 37:578–588.PubMedCrossRef 41. O’Byrne KJ, Danson S, Dunlop D, Botwood N, Taguchi F, Carbone D, Ranson M: Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non-small-cell lung cancer. J Clin Oncol 2007, 25:3266–3273.PubMedCrossRef 42. Gadgeel SM, Metformin molecular weight Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A: Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2007, 2:299–305.PubMedCrossRef Competing interests We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, and there is no professional or other personal ACY-1215 in vitro interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the enclosed manuscript.

Comments are closed.